← back to search

Fortunato Morabito

Azienda Sanitaria Unità Locale di Reggio Emilia · IT
🔎 Find collaborators in Genetics · Hematology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Genetics · Hematology
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment, and Immunodeficiency and Autoimmune Disorders.
h-index
56
citations
11,988
works
676
NIH funding
primary concept
Medicine
email

Recent publications

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.
2026cited by 1position: contributordoi
Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational Opportunities.
2026cited by 0position: contributordoi
The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities.
2026cited by 0position: contributordoi
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia
2026cited by 0position: contributordoi
Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort.
2026cited by 0position: contributordoi
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia.
2026cited by 0position: contributordoi
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions.
2025cited by 14position: contributordoi
Avatrombopag for the Treatment of Immune Thrombocytopenia.
2025cited by 5position: contributordoi
Advances and Challenges in Quizartinib-Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies.
2025cited by 4position: contributordoi
Rilzabrutinib for the Treatment of Immune Thrombocytopenia.
2025cited by 3position: contributordoi
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives.
2025cited by 3position: contributordoi
Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies.
2025cited by 3position: contributordoi
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions.
2025cited by 2position: contributordoi
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.
2025cited by 1position: contributordoi
Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights.
2025cited by 0position: contributordoi
Impact of COVID-19 on the Stage and Treatment of Endometrial Cancer: A Cancer Registry Analysis from an Italian Comprehensive Cancer Center.
2025cited by 0position: contributordoi
Teclistamab-cqyv in multiple myeloma.
2024cited by 15position: contributordoi
Impact of the COVID-19 Pandemic on Prostate Cancer Diagnosis, Staging, and Treatment: A Population-Based Study in Northern Italy.
2024cited by 6position: contributordoi
Outcomes before and after Implementation of the ERAS (Enhanced Recovery after Surgery) Protocol in Open and Laparoscopic Colorectal Surgery: A Comparative Real-World Study from Northern Italy.
2024cited by 4position: contributordoi
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
2024cited by 4position: contributordoi
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.
Preprints.org 2024cited by 2position: middledoi
A Population-Based Analysis of the Cancer Incidence in Individuals under 50 in a Northern Italian Province: Focusing on Regional Disparities and Public Health Implications.
2024cited by 1position: contributordoi
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.
2024cited by 1position: contributordoi
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study
Non-Coding RNA 2024cited by 1position: middledoi
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.
2024cited by 0position: contributordoi
Iron chelation therapy.
2023cited by 49position: contributordoi
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
Leukemia 2023cited by 21position: middledoi
Optimizing Outcomes through a Multidisciplinary Team Approach in Endometrial Cancer.
2023cited by 5position: contributordoi
Incidence and Survival of Testicular Cancers in a Province in Northern Italy and Their Association with Second Tumors.
2023cited by 3position: contributordoi
The Impact of COVID-19 on New Kidney Cancer Diagnosis: Stage and Treatment in Northern Italy.
2023cited by 3position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 37 papers (2020–2026)Massimo Gentile · Weatherford College20 papers (2013–2026)Giovanna Cutrona · Alleanza Contro il Cancro19 papers (2013–2026)Antonino Neri · University of Milan18 papers (2013–2025)Antonella Bruzzese · Azienda Ospedaliera di Cosenza12 papers (2023–2025) · 11 papers (2020–2026) · 10 papers (2020–2026)Francesco Marinelli · Azienda Unità Sanitaria Locale - IRCCS Tecnologie Avanzate e Modelli Assistenziali in Oncologia di Reggio Emilia8 papers (2023–2025)Lucia Mangone · University of Parma8 papers (2023–2025)Isabella Bisceglia · Azienda Sanitaria Unità Locale di Reggio Emilia8 papers (2023–2025)Manlio Ferrarini · Ospedale Policlinico San Martino7 papers (2013–2024)Massimo Negrini · The Ohio State University6 papers (2013–2024)Paola Monti · Alleanza Contro il Cancro6 papers (2020–2024)Monica Colombo · University of Ferrara5 papers (2013–2024)Carmine Pinto · University of Salerno5 papers (2023–2024)Sabrina Bossio · University of Ferrara5 papers (2013–2020)Anna Grazia Recchia · University of Ferrara5 papers (2013–2020)Monica Colombo · Ospedale Policlinico San Martino5 papers (2024–2026) · 5 papers (2020–2025) · 5 papers (2023–2024)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Genetics · Hematology →